Intercept Pharmaceuticals Inc. (NASDAQ:ICPT)‘s stock had its “outperform” rating reaffirmed by analysts at Wedbush in a research report issued on Saturday. They presently have a $224.00 price target on the biopharmaceutical company’s stock. Wedbush’s target price indicates a potential upside of 93.37% from the company’s current price.

Several other brokerages have also issued reports on ICPT. Wells Fargo & Co. reissued a “buy” rating on shares of Intercept Pharmaceuticals in a research report on Wednesday, September 28th. Robert W. Baird reissued an “outperform” rating and issued a $332.00 target price on shares of Intercept Pharmaceuticals in a research report on Thursday, September 22nd. Credit Suisse Group AG reissued a “buy” rating on shares of Intercept Pharmaceuticals in a research report on Thursday, September 22nd. JMP Securities restated a “buy” rating on shares of Intercept Pharmaceuticals in a research note on Thursday, August 18th. Finally, FBR & Co restated a “market perform” rating and issued a $200.00 price target on shares of Intercept Pharmaceuticals in a research note on Thursday, August 18th. Five investment analysts have rated the stock with a sell rating, four have assigned a hold rating and eleven have assigned a buy rating to the company’s stock. Intercept Pharmaceuticals currently has an average rating of “Hold” and a consensus price target of $177.07.

Analyst Recommendations for Intercept Pharmaceuticals (NASDAQ:ICPT)

Shares of Intercept Pharmaceuticals (NASDAQ:ICPT) traded up 1.37% during mid-day trading on Friday, reaching $115.84. The company had a trading volume of 207,545 shares. The company has a 50 day moving average price of $124.14 and a 200 day moving average price of $145.79. The company’s market capitalization is $2.87 billion. Intercept Pharmaceuticals has a one year low of $89.76 and a one year high of $186.87.

Intercept Pharmaceuticals (NASDAQ:ICPT) last announced its earnings results on Thursday, November 3rd. The biopharmaceutical company reported ($3.59) earnings per share (EPS) for the quarter, topping the consensus estimate of ($3.82) by $0.23. Intercept Pharmaceuticals had a negative return on equity of 66.97% and a negative net margin of 3,287.95%. The firm earned $4.70 million during the quarter, compared to analyst estimates of $4.77 million. During the same quarter in the prior year, the company earned ($2.10) EPS. The business’s revenue was up 1051.1% compared to the same quarter last year. On average, analysts anticipate that Intercept Pharmaceuticals will post ($15.63) EPS for the current year.

TRADEMARK VIOLATION WARNING: “Intercept Pharmaceuticals Inc. (ICPT) Earns Outperform Rating from Wedbush” was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece of content on another website, it was illegally copied and reposted in violation of U.S. & international trademark and copyright laws. The legal version of this piece of content can be accessed at https://www.thecerbatgem.com/2016/11/27/intercept-pharmaceuticals-inc-icpt-earns-outperform-rating-from-wedbush.html.

In other Intercept Pharmaceuticals news, CMO David Shapiro sold 3,545 shares of the firm’s stock in a transaction dated Monday, September 26th. The stock was sold at an average price of $165.08, for a total transaction of $585,208.60. Following the sale, the chief marketing officer now directly owns 45,732 shares of the company’s stock, valued at $7,549,438.56. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Mark Pruzanski sold 35,000 shares of the firm’s stock in a transaction dated Tuesday, September 20th. The shares were sold at an average price of $165.00, for a total value of $5,775,000.00. Following the sale, the chief executive officer now directly owns 579,314 shares in the company, valued at $95,586,810. The disclosure for this sale can be found here. Company insiders own 9.20% of the company’s stock.

A number of large investors have recently bought and sold shares of the stock. CENTRAL TRUST Co acquired a new stake in Intercept Pharmaceuticals during the second quarter worth approximately $107,000. The Manufacturers Life Insurance Company acquired a new stake in Intercept Pharmaceuticals during the third quarter worth approximately $114,000. KBC Group NV boosted its stake in Intercept Pharmaceuticals by 660.2% in the third quarter. KBC Group NV now owns 897 shares of the biopharmaceutical company’s stock worth $147,000 after buying an additional 779 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in Intercept Pharmaceuticals by 67.9% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 915 shares of the biopharmaceutical company’s stock worth $151,000 after buying an additional 370 shares in the last quarter. Finally, Legal & General Group Plc boosted its stake in Intercept Pharmaceuticals by 4.5% in the second quarter. Legal & General Group Plc now owns 1,196 shares of the biopharmaceutical company’s stock worth $171,000 after buying an additional 52 shares in the last quarter. 81.54% of the stock is currently owned by institutional investors and hedge funds.

Intercept Pharmaceuticals Company Profile

Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.

5 Day Chart for NASDAQ:ICPT

Receive News & Stock Ratings for Intercept Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.